Novozymes, Cargill Continue Bio-Acrylic Acid Partnership as BASF Exits
News Jan 28, 2015
Chemical company BASF has decided to exit the current R&D collaboration with Novozymes and Cargill to develop a bio-based process for producing 3-hydroxypropionic (3-HP) and acrylic acid from renewable raw materials.
Germany based BASF joined the collaboration with Novozymes and Cargill in 2012 and are now leaving the partnership. Novozymes and Cargill have collaborated on the project since 2008 and will continue their work to commercialize bio-based 3-HP and derivatives. The two companies have initiated efforts to find a new commercialization partner.
“We are continuing our work with Novozymes to commercialize 3-HP to bio-based chemicals, including acrylic acid to bring our customers more sustainable alternatives to fossil-based chemicals,” says Cargill’s Vice President of Research and Development, Jack Staloch.
“This is pioneering biochemical research, and the technology development and achievements so far have been extraordinary,” says Kristian Bjørneboe, Vice President for Business Creation and Acquisition at Novozymes.
Technical and business targets achieved
The R&D cooperation on bio-based acrylic acid has achieved the technical and business targets. In 2013, the project accomplished the production of 3-HP in pilot scale, and in September 2014 announced the successful conversion of 3-HP to glacial acrylic acid and superabsorbent polymers.
Acrylic acid is a high-volume chemical that feeds into a broad range of products. One of the main applications is in the manufacture of superabsorbent polymers that can soak up large amounts of liquid and are used mainly in baby diapers and other hygiene products.
Acrylic acid is also used in adhesive raw materials and coatings. Presently, acrylic acid is produced by the oxidation of propylene derived from the refining of crude oil.
Innovative ALS Therapy Startup Wins Golden Ticket Funding From AmgenNews
Amgen and LabCentral have announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral.READ MORE
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE